Uncategorized
EyeGate grants Valeant rights to EGP-437 combination product
EyeGate Pharmaceuticals has signed a licensing agreement with Valeant Pharmaceuticals for rights to the EyeGate II Delivery System and EGP-437 combination product to treat uveitis, according to a company release.“This licensing agreement provides a significant validation for the EGP-437 combination product and has transformative potential for EyeGate,” Stephen From, president and CEO of EyeGate, said in the release. “Valeant is among the largest and most respected companies in the ophthalmology space, and we are thrilled to be working with them to advance our lead product candidate.”